CAMBRIDGE, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia, as well as novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited financial results for the quarter and six months ended June 30, 2007. On May 14, 2007, the Company changed its fiscal year end from September 30 to December 31. Accordingly, the unaudited financial results contained in this press release reflect the Company’s new fiscal year end and therefore, the year-to-date amounts are for the six-month periods ended June 30, 2007 and 2006.
